Healthcare

Accelerating Growth and Enhancing Value for Healthcare

Roth’s Healthcare Team provides financing and strategic advisory services for public and private companies in the life sciences sector. Our clients include both development and commercial stage companies and include companies engaged in the development of novel therapeutic compounds, the application of unique drug discovery and drug delivery technologies, and the development and marketing of biopharmaceuticals, specialty pharmaceuticals, medical devices and diagnostics.

Roth works closely with our clients’ management teams and boards of directors to determine and execute optimal financing strategies. Roth has an extensive track record in executing IPOs, follow-on offerings, PIPEs, registered directs and confidentially marketed public offerings for life sciences companies.

Additionally, Roth also advises our clients on strategic transactions, including mergers, acquisitions, divestitures, reverse mergers, strategic sales, licensing agreements and strategic partnerships, and provides fairness opinions related to such transactions.

Investment Banking

Sector Focus

  • Biotechnology
  • Specialty pharmaceuticals
  • Medical devices
  • Diagnostics

Investment Banking Team

James Antonopoulos

Managing Director, Head of Healthcare Investment Banking

Benjamin Bowen, Ph.D.

Managing Director, Investment Banking

Aparna Beeram

Senior Vice President, Investment Banking

Select Transactions

View All Transactions

$16,000,000

Biofrontera Inc.

PIPE

Sole Placement Agent February 2024

$9,012,000

Panbela Therapeutics, Inc.

Follow-On

Sole Placement Agent January 2024

$18,000,000

Helius Medical Technologies, Inc.

Follow-On

Lead Placement Agent August 2022

$35,881,000

Genenta Science

IPO

Sole Book-Running Manager December 2021

$23,000,000

Biorestorative Therapies, Inc.

Follow-On

Sole Manager November 2021

$16,653,000

RenovoRx Inc.

IPO

Sole Book-Running Manager August 2021

$25,000,000

Unicycive Therapeutics, Inc.

IPO

Sole Manager July 2021

$39,970,000

TFF Pharmaceuticals, Inc.

Follow-On

Sole Book-Running Manager March 2021

Research

Research Team

Jason Wittes

Managing Director, Senior Research Analyst

View Profile

Jonathan Aschoff, Ph.D.

Managing Director, Senior Research Analyst

View Profile

Scott Fortune

Managing Director, Senior Research Analyst

View Profile